Latest Breaking News On - Cyte contacts - Page 6 : vimarsana.com

Investegate |MaxCyte, Inc. Announcements | MaxCyte, Inc.: Participation in Upcoming Investor Conferences

Investegate announcements from MaxCyte, Inc., Participation in Upcoming Investor Conferences

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

Investegate |MaxCyte, Inc. Announcements | MaxCyte, Inc.: Total Voting Rights and Block Listing Return

Investegate announcements from MaxCyte, Inc., Total Voting Rights and Block Listing Return

Investegate |MaxCyte, Inc. Announcements | MaxCyte, Inc.: Signing of Strategic Platform License

Investegate announcements from MaxCyte, Inc., Signing of Strategic Platform License

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™... | September 28, 2022

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's I-270 Biotech Corridor

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor - read this article along with other careers information, tips and advice on BioSpace

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's I-270 Biotech Corridor · BioBuzz

MaxCyte Debuts New State-of-the-Art Headquarters in

Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling...

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's I-270 Biotech Corridor

Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local

MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

07.09.2022 - ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as ...